Showing results (21-30 of 63) with videos related to
Sort By:
Pageof 7
Frontiers in Immunology|June 11, 2019
Systems Immunology Characterization of Novel Vaccine Formulations for <i>Mycoplasma hyopneumoniae</i> BacterinsAnneleen M F Matthijs, Gaël Auray, Virginie Jakob, et al.Scientific Reports|August 11, 2017
The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skinCharlotte Deloizy, Even Fossum, Christophe Barnier-Quer, et al.Human Vaccines & Immunotherapeutics|August 23, 2013
Modern Vaccines/Adjuvants Formulation--Session 2 (Plenary II): May 15-17, 2013--Lausanne, SwitzerlandNicolas CollinJournal of Controlled Release : Official Journal of the Controlled Release Society|July 3, 2019
Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigsCindy Bernelin-Cottet, Céline Urien, Joanne McCaffrey, et al.Frontiers in Cellular and Infection Microbiology|July 5, 2022
Designing Adjuvant Formulations to Promote Immunogenicity and Protective Efficacy of <i>Leptospira</i> Immunoglobulin-Like Protein A Subunit VaccineTeerasit Techawiwattanaboon, Thomas Courant, Livia Brunner, et al.Frontiers in Cellular and Infection Microbiology|September 3, 2025
Correction: Designing adjuvant formulations to promote immunogenicity and protective efficacy of <i>Leptospira</i> immunoglobulin-like protein a subunit vaccineTeerasit Techawiwattanaboon, Thomas Courant, Livia Brunner, et al.Mbio|March 12, 2020
Vaccine-Induced Th1-Type Response Protects against Invasive Group A <i>Streptococcus</i> Infection in the Absence of Opsonizing AntibodiesTania Rivera-Hernandez, Mira Syahira Rhyme, Amanda J Cork, et al.Vaccine|July 1, 2009
Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenzaNicolas Collin, Xavier de Radiguès, Vaccine|June 21, 2011
The Vaccine Formulation Laboratory: a platform for access to adjuvantsNicolas Collin, Patrice M DuboisJournal of Hepatology|January 12, 2023
Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse modelsJinpeng Su, Livia Brunner, Edanur Ates Oz, et al.Pageof 7